ITCI FY2025 EPS Estimate Lowered by Cantor Fitzgerald

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Intra-Cellular Therapies in a research note issued to investors on Monday, February 24th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will post earnings per share of ($0.51) for the year, down from their prior forecast of ($0.25). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Intra-Cellular Therapies' current full-year earnings is ($0.64) per share.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%.

ITCI has been the topic of a number of other research reports. JPMorgan Chase & Co. increased their price target on Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an "overweight" rating in a research report on Monday, November 4th. Canaccord Genuity Group lowered Intra-Cellular Therapies from a "buy" rating to a "hold" rating and increased their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Baird R W lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Mizuho lowered Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Ten research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $106.08.

Intra-Cellular Therapies Stock Performance

ITCI stock traded down $0.05 during mid-day trading on Wednesday, reaching $128.20. The company had a trading volume of 1,486,294 shares, compared to its average volume of 3,849,049. The company has a market capitalization of $13.63 billion, a price-to-earnings ratio of -147.35 and a beta of 0.72. The firm has a fifty day simple moving average of $114.58 and a 200 day simple moving average of $91.50. Intra-Cellular Therapies has a fifty-two week low of $63.30 and a fifty-two week high of $129.00.

Insider Buying and Selling

In related news, CEO Sharon Mates sold 51,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ITCI. Accredited Wealth Management LLC purchased a new position in Intra-Cellular Therapies during the 4th quarter worth approximately $28,000. True Wealth Design LLC purchased a new position in shares of Intra-Cellular Therapies in the 3rd quarter valued at approximately $32,000. GAMMA Investing LLC grew its stake in shares of Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 240 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Intra-Cellular Therapies in the 3rd quarter valued at approximately $74,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies in the 4th quarter valued at approximately $96,000. Hedge funds and other institutional investors own 92.33% of the company's stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.